KIF18A and ovarian cancer: KIF18A inhibitor treatment across the large-scale pan-cancer PRISM panel (629 cell lines) revealed that 25% of cancers overall and 32% of ovarian cancers exhibited strong KIF18A dependency (Payton et al, 2023).